2013
The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary
Saliminejad M, Bemanian S, Ho A, Spiegel B, Laine L. The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary. Alimentary Pharmacology & Therapeutics 2013, 38: 628-633. PMID: 23869398, DOI: 10.1111/apt.12429.Peer-Reviewed Original ResearchMeSH KeywordsColonic NeoplasmsColonoscopyCost of IllnessCost-Benefit AnalysisFemaleHumansMaleMiddle AgedNeoplasms, Unknown PrimaryProspective StudiesRetrospective StudiesConceptsPrimary colon cancerCost of colonoscopyColon cancerColon primaryUnknown primaryMetastatic cancerVeterans Administration Medical CenterPalpable rectal massPrior colon cancerIron deficiency anemiaOccult bleedingAdvanced diseaseRectal massStandard indicationsDiagnostic colonoscopyEnrollment criteriaRoutine colonoscopyTargeted therapyColorectal lesionsMedical CenterExclusion criteriaColonoscopyPatientsCancer syndromesCancerGastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance
de Groot NL, van Haalen HG, Spiegel BM, Laine L, Lanas A, Focks JJ, Siersema PD, van Oijen MG. Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance. Cardiovascular Drugs And Therapy 2013, 27: 341-357. PMID: 23417566, DOI: 10.1007/s10557-013-6448-y.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinCost-Benefit AnalysisDrug Therapy, CombinationGastrointestinal HemorrhageHealth Care CostsHumansMaleMiddle AgedModels, TheoreticalPatient CompliancePlatelet Aggregation InhibitorsPrimary PreventionProton Pump InhibitorsQuality-Adjusted Life YearsSecondary PreventionConceptsAcute coronary syndromeProton pump inhibitorsUpper GI bleedingSecondary preventionGI bleedingASA monotherapyPPI complianceElevated riskLow-dose ASA usersLow-dose aspirin usersUpper GI side effectsGI side effectsUpper gastrointestinal complicationsCombination of ASABase-case patientProbabilistic sensitivity analysesCost-effectiveness analysisASA usersGastrointestinal complicationsGastroprotective strategiesAspirin usersCoronary syndromePPI useACS eventCase patients
2003
Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company. Gastroenterology 2003, 125: 389-395. PMID: 12891540, DOI: 10.1016/s0016-5085(03)00900-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalCohort StudiesCost-Benefit AnalysisCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsFemaleGastrointestinal DiseasesHealth ResourcesHumansIsoenzymesLongitudinal StudiesMaleMembrane ProteinsMiddle AgedProstaglandin-Endoperoxide SynthasesRetrospective StudiesConceptsChronic NSAID therapyCoxib therapyNSAID therapyChronic nonsteroidal anti-inflammatory drug (NSAID) therapyNonsteroidal anti-inflammatory drug therapyAnti-inflammatory drug therapyHealth care resource utilizationCOX-2-specific inhibitorsU.S. administrative claims databaseMedco Health SolutionsProportion of patientsAdministrative claims databaseGastrointestinal eventsNewer coxibsInitial prescriptionChronic useClaims databaseDrug therapyClinical trialsDrug costsNew NSAIDClinical practicePatientsTherapyAbstractText